title: Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
authors.affiliation: Department of Transplantation Medicine, New York Presbyterian Hospital/Weill Cornell Medical College, New York, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Lubetzky
authors.forename: Meredith J
authors.initials: MJ
authors.lastname: Auli
authors.forename: Jennifer
authors.initials: J
authors.lastname: Walker
authors.forename: David
authors.initials: D
authors.lastname: Leeser
authors.forename: Sandip
authors.initials: S
authors.lastname: Kapur
authors.forename: Choli
authors.initials: C
authors.lastname: Hartono
authors.forename: Darshana
authors.initials: D
authors.lastname: Dadhania
mesh_terms: D000328:Adult; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009519:New York City; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011507:Proteinuria / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex